Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 705 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Severe Side Effects of Cancer Treatment Are More Common in Women... March 15, 2022 Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients... December 12, 2025 FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib... May 30, 2025 In memory of Dame Deborah James June 29, 2022 Load more HOT NEWS 10 Ways the Inflation Reduction Act will Impact Cancer Care More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease Sacituzumab Govitecan Prolongs Survival in Relapsed or Refractory Metastatic Triple Negative... First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield...
